在2016年，我们介绍了丹麦前列腺癌登记处（DaPCaR），其建立基于1995年至2011年的全国病理登记处。由于大部分数据需要手动输入且没有定期更新，DaPCaR的使用较为繁琐。在这里，我们介绍了一种新的综合性集中前列腺登记处，称为丹麦前列腺登记处（DanProst），其包括所有进行了前列腺组织的任何组织学评估的男性，并与实验室、治疗、处方数据以及生命状况合并。以下描述了DanProst所包含的数据和方法。DanProst是基于丹麦国家病理登记处的所有经过前列腺组织组织学评估的男性建立的。针对每个独特个体，提取并通过新制作的有关部位、操作、诊断结论和病理分期的算法进行翻译。从DaPCaR、CPR登记处、丹麦死因登记处、丹麦癌症登记处、全国患者登记处、丹麦研究实验室结果登记处和丹麦全国处方登记处进一步添加信息。翻译算法在2010年至2016年期间与DaPCaR进行了比较验证。DanProst包括190,422名男性。截至2021年，共有95,152（50%）名男性被诊断为前列腺癌。中位数诊断前列腺特异性抗原（PSA）为11ng/ml，大部分男性通过超声引导活检被诊断（N = 63,751；67%），最常见的初级治疗定义为根治性前列腺切除术（N = 14,778；19%）。DanProst与DaPCaR的一致性分别为> 99%、95%和94%。DanProst是一个持续更新、集中保持的经过验证的登记处，可以自动整合来自其他国家登记处的数据，允许对进行前列腺组织组织学评估的男性进行当代全国范围的分析。©2023年。作者。

In 2016, we introduced the Danish Prostate Cancer Registry (DaPCaR) which was built on the National Pathology Register from 1995 to 2011. DaPCaR was laborious to use as most data had to be manually imputed with no regular updates. In here we present a new comprehensive centralized prostate registry called the Danish Prostate Registry (DanProst), which includes all men having undergone any histological evaluation of prostate tissue merged with laboratory-, treatment-, prescription data as well as vital status. Here the data included and the methodology of DanProst are described. DanProst is built upon all men with a histological assessment of the prostate from the Danish National Registry for Pathology. The primary histology and potential prostate cancer histological diagnosis for each unique individual is extracted and translated by newly made algorithms for topography, procedure, diagnostic conclusion, and pathological staging. Further information is added from DaPCaR, the CPR Registry, the Danish Cause of Death Registry, the Danish Cancer Registry, the National Patient Registry, the Danish Register of Laboratory Results for Research, and the Danish National Prescription Registry. The translation algorithms were validated based on the comparison with DaPCaR in the period 2010-2016. DanProst includes 190,422 men. A total of 95,152 (50%) men are diagnosed with prostate cancer until 2021. Median diagnostic PSA was 11 ng/ml, most men are diagnosed by ultrasound-guided biopsy (N = 63,751; 67%), and most frequently defined primary treatment was radical prostatectomy (N = 14,778; 19%). DanProst to DaPCaR coherency was > 99%, 95%, and 94% for the primary histological procedure, primary histological conclusion, and diagnostic histological conclusion, respectively. DanProst is a continuously updated, centrally kept, validated registry with automatic integration of data from other national registries, allowing for contemporary nationwide analysis in men with histological assessment of the prostate.© 2023. The Author(s).